Is the Frequency of Candidemia Increasing in COVID-19 Patients Receiving Corticosteroids?
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Author Contributions
Funding
Conflicts of Interest
References
- The RECOVERY Collaborative Group; Horby, P.; Lim, W.S.; Emberson, J.R.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; et al. Dexamethasone in hospitalized patients with Covid-19-Preliminary report. N. Engl. J. Med. 2020. [Google Scholar] [CrossRef]
- The Writing Committee for the REMAP-CAP Investigators; Angus, D.C.; Derde, L.; Al-Beidh, F.; Annane, D.; Arabi, Y.; Beane, A.; Van Bentum-Puijk, W.; Berry, L.; Bhimani, Z.; et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19. JAMA 2020, 324, 1317. [Google Scholar] [CrossRef] [PubMed]
- Tomazini, B.M.; Maia, I.S.; Cavalcanti, A.B.; Berwanger, O.; Rosa, R.G.; Veiga, V.C.; Avezum, A.; Lopes, R.D.; Bueno, F.R.; Silva, M.V.A.O.; et al. Effect of Dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. JAMA 2020, 324, 1307. [Google Scholar] [CrossRef] [PubMed]
- Dequin, P.-F.; Heming, N.; Meziani, F.; Plantefève, G.; Voiriot, G.; Badié, J.; François, B.; Aubron, C.; Ricard, J.-D.; Ehrmann, S.; et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19. JAMA 2020, 324, 1298. [Google Scholar] [CrossRef] [PubMed]
- Ng, T.T.; Robson, G.D.; Denning, D.W. Hydrocortisone-enhanced grow of Aspergillus spp.: Implications for pathogenesis. Microbiology 1994, 140, 2475–2479. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lionakis, M.S.; Kontoyiannis, D.P. Glucocorticoids and invasive fungal infections. Lancet 2003, 362, 1828–1838. [Google Scholar] [CrossRef]
- Brazilian Health Regulatory Agency—ANVISA. Technical Note GVIMS/GGTES/ANVISA No 07/2020. In Guidelines for Prevention and Epidemiologic Surveillance of SARS-CoV-2 (COVID-19) Infections within Health Services; Brazilian Health Regulatory Agency—ANVISA: Brasilia, Brazil, 2020. [Google Scholar]
- Emergency Operations Center in Public Health—COE/SES-RS. Informative Note 24 COE/SES-RS. In Surveillance of Influenza-like Syndrome and Severe Acute Respiratory Syndrome (SARS) Related to COVID-19 Human Infection, Surveillance Systems, Laboratory Network and Testing Strategies; Emergency Operations Center in Public Health—COE/SES-RS: Porto Alegre, Brazil, 2020. [Google Scholar]
- Abramson, J.H. WINPEPI updated: Computer programs for epidemiologists, and their teaching potential. Epidemiol. Perspect. Innov. 2011, 8, 1. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062. [Google Scholar] [CrossRef]
- Baqui, P.; Bica, I.; Marra, V.; Ercole, A.; Van Der Schaar, M. Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: A cross-sectional observational study. Lancet Glob. Health 2020, 8, e1018–e1026. [Google Scholar] [CrossRef]
- Hughes, S.; Troise, O.; Donaldson, H.; Mughal, N.; Moore, L. Bacterial and fungal coinfection among hospitalized patients with COVID-19: A retrospective cohort study in a UK secondary-care setting. Clin. Microbiol. Infect. 2020, 26, 1395–1399. [Google Scholar] [CrossRef] [PubMed]
- Lansbury, L.; Lim, B.; Baskaran, V.; Lim, W.S. Co-infections in people with COVID-19: A systematic review and meta-analysis. J. Infect. 2020, 81, 266–275. [Google Scholar] [CrossRef] [PubMed]
Pt | Age/Sex | Underlying Conditions | Date of Admission | COVID-19 Management | ICU Days until Isolation/Candida Species | Risk Factors for Candidemia | Treatment and Outcome |
---|---|---|---|---|---|---|---|
1 | 44/M | DM, dyslipidemia, psoriasis, schizophrenia | 13 April 2020 | Chloroquine 4 d AZI, IVE MPD 1 g qd 2 d, then 80 mg bid 9 d and reduction | No ICU admission C. albicans | DM CVC 20 days PTZ 5 days MEM 8 days | AFG Discharged |
2 | 71/F | HT, coronary artery disease | 14 May 2020 | AZI MPD 62.5 mg bid 2 d | 1 day C. glabrata | CVC 7 days Ceftriaxone 2 d. PTZ 7 days | Death prior to treatment |
3 | 69/F | DM, HT, obesity, cardiac failure, COPD | 16 May 2020 | HCQ 1 day a/AZI MPD 62.5 mg tid 7 d | 9 days C. glabrata | DM, CVC 9 days Oxacillin 4 days PTZ 7 days | AFG Death |
4 | 37/F | Asthma | 1 July 2020 | AZI, IVE MPD 62.5 mg tid 2 d., then DXM 6 mg qd 3 d., MPD 62.5 mg quad 8 d | 8 days C. albicans | CVC 8 days AMC 5 days PTZ 7 days | AMB-d FLC Death |
5 | 87/F | HT, atrial fibrillation | 10 July 2020 | AZI, IVE MPD 62.5 mg tid 2 d., bid 2 d., and qd 3 d | 6 days C. tropicalis | CVC 7 days PTZ 6 days | AFG Death |
6 | 66/M | HT | 26 July 2020 | AZI, IVE MPD 1 g qd 2 d., then 500 mg qd 1 day, DXM 6 mg qd 9 d | 14 days C. albicans | CVC 14 days Cefuroxime 5 d. PTZ 8 days MEM 3 days | AFG Discharged |
7 | 91/M | Asthma | 29 July 2020 | MPD 250 mg qd 1 d., then DXM 6 mg qd 7 d | 7 days C. albicans | CVC 7 days Amoxicillin 5 d. PTZ 7 days | AFG Death |
8 | 54/M | DM, HT, obesity, Raynaud synd., depression | 8 August 2020 | AZI DXM 6 mg qd 5 d | Day of ICU admission C. albicans | DM AMC 6 days PTZ 2 days | FLC Discharged |
9 | 41/M | HIV, HCV, myocardiopathy | 15 August 2020 | Prednisone 40 mg qd 4 d | Day of ICU admission C. albicans | HIV CVC 10 days | FLC Death |
10 | 57/M | DM, HT | 23 July 2020 b | AZI DXM 6 mg qd 10 d | 22 days C. albicans | DM CVC 22 days AMC 5 days PTZ 8 days | Voriconazole AFG Death |
11 | 59/M | HT, chronic renal disease, mental impairment | 23 August 2020 | DXM 6 mg qd 3 d., then Hydrocortisone 50 mg qid 4 d | 3 days C. albicans | CVC 4 days AMC 4 days | FLC Death |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Riche, C.V.W.; Cassol, R.; Pasqualotto, A.C. Is the Frequency of Candidemia Increasing in COVID-19 Patients Receiving Corticosteroids? J. Fungi 2020, 6, 286. https://doi.org/10.3390/jof6040286
Riche CVW, Cassol R, Pasqualotto AC. Is the Frequency of Candidemia Increasing in COVID-19 Patients Receiving Corticosteroids? Journal of Fungi. 2020; 6(4):286. https://doi.org/10.3390/jof6040286
Chicago/Turabian StyleRiche, Cezar V. W., Renato Cassol, and Alessandro C. Pasqualotto. 2020. "Is the Frequency of Candidemia Increasing in COVID-19 Patients Receiving Corticosteroids?" Journal of Fungi 6, no. 4: 286. https://doi.org/10.3390/jof6040286